Firm Seeks License to Import Controlled Substances
Published Date: 6/15/2026
Notice
Summary
Cerilliant Corporation wants to become an official importer of certain controlled substances, including some drugs that need strict government oversight. People and companies involved with these substances can share their thoughts or ask for a hearing by July 15, 2026. This move could affect how these drugs enter the U.S. and might impact businesses handling them.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Cerilliant applied to import many controlled substances
On May 8, 2026, Cerilliant Corporation applied to be registered to import the long list of Schedule I and II controlled substances shown in the notice as bulk Active Pharmaceutical Ingredients to support making analytical reference standards and distributing them to research and forensic customers. Registered bulk manufacturers and applicants may submit comments or objections, or request a hearing, on or before July 15, 2026.
Import limited to bulk APIs; no finished dosage forms
The notice states that any registration, if approved, will authorize only importation of the listed substances as bulk Active Pharmaceutical Ingredients for analytical reference standards and distribution to research and forensic customers. Authorization will not extend to importing Food and Drug Administration–approved or non-approved finished dosage forms for commercial sale.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-11572 — Ashley Vermillion, N.P.; Decision and Order
Ashley Vermillion, a nurse practitioner from Maine, lost her DEA registration because she no longer has the legal right to handle controlled substances in her state. She didn’t ask for a hearing, so the DEA moved forward and officially revoked her registration. This means she can’t prescribe or manage controlled drugs anymore, effective immediately.
2026-11416 — Importer of Controlled Substances Application: CalCog Inc.
CalCog Inc. wants to become an official importer of some powerful controlled substances like LSD and 5-MeO-DMT. People and companies involved with these drugs have until July 8, 2026, to share their thoughts or ask for a hearing. This move could shake up the import scene, but no costs or changes happen until the DEA decides.
2026-10380 — Schedules of Controlled Substances: Placement of Diphenidine in Schedule I
The DEA wants to put diphenidine, a drug, into Schedule I, which means it will be treated like the most tightly controlled substances. This change affects anyone who makes, sells, studies, or owns diphenidine, adding strict rules and penalties. You’ve got until June 25, 2026, to share your thoughts before the new rules might kick in.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
Previous / Next Documents
Previous: 2026-11907 — Certain TOPCon Solar Cells, Modules, Panels, Components Thereof, and Products Containing Same; Notice of a Commission Determination Not To Review an Initial Determination Granting Tesla, Inc.'s Motion To Intervene
Tesla just got the green light to join a big investigation about certain TOPCon solar products that might be breaking patent rules. This affects companies making or selling these solar cells and panels in the U.S., and it could shake up the solar market soon. Keep an eye out for updates because this could impact prices and who gets to sell these solar goodies.
Next: 2026-11910 — Bulk Manufacturer of Controlled Substances Application: Veranova, L.P.
Veranova, L.P. wants to become a big-time maker of many controlled substances like fentanyl, marijuana, and methamphetamine. This means they’ll produce these drugs in large amounts to sell to customers and use in their own processes. People and companies can share their thoughts or ask for a hearing by August 14, 2026, so don’t miss the deadline!